Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

2X-121 · E-7449

Small molecule · Inhibitor of PARP (PARP1) · developed by Allarity Therapeutics

Phase 2 Most advanced trial

ALLR Developer

3 Registered trials

What is 2X-121?

2X-121 is a PARP inhibitor administered orally as a small molecule. It is being studied in advanced ovarian cancer, metastatic breast cancer, and advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: E-7449
Drug type: Small molecule
Targets: PARP (PARP1)
Mechanism: Inhibitor of PARP (PARP1)
Pathways: DNA repair, apoptosis
Therapy area: Oncology
Developer: Allarity Therapeutics (ALLR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 9X5A2QIA7C

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03878849	Phase 2	Advanced Ovarian Cancer	Recruiting	ALLR
NCT03562832	Phase 2	Metastatic Breast Cancer	Completed	ALLR
NCT05571969	Phase 1	Advanced Solid Tumors	Terminated	ALLR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Ovarian CancerAdvanced Solid TumorsMetastatic Breast Cancer

Other drugs acting on PARP1

Niraparib FDA approved Olaparib FDA approved EIK1004 Investigational IMP1734 Investigational Senaparib Investigational Veliparib Phase 1

More from Allarity Therapeutics

APO010 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ALLR page.

Follow ALLR, the company behind 2X-121

See ALLR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALLR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z